| Description | This product is a neutralizing antibody that binds to Severe Acute Respiratory Syndrome Coronavirus 2. COV2-2196 is capable of specifically binding with SARS-CoV-2 and shows a good capacity to neutralize the SARS-CoV-2. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Epitope | RBD receptor binding domain |
| Isotype | IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA |
| Application Notes | Binding ELISA were used to confirm the epitope specificities of DMAbs 2130, 2196 and 2381. NUNC 96-well MaxiSorp plates were coated with recombinant RBD proteins (3 µg /ml in 1× PBS) containing mutations at residues F444A or F486, which are key residues required for the binding of clones 2130 and 2196/2381, respectively. To evaluate the relative binding of each construct to different VoC, the following coating antigens were used: SARS-CoV-2 Spike RBD-His Recombinant Protein, Spike S1(D614G)-His Recombinant Protein, RBD-His K417N Recombinant Protein, RBD-His E484K Recombinant Protein, RBD-His N501Y, Spike S1-K417N/E484K/N501Y/D614G Recombinant Protein, B.1.1.529(BA.1) S1 + S2 Trimer-His Recombinant Protein. ELISA procedure was completed as described above. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
